Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 2
Opinion
Video
Challenges of BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- BCG therapy resistance in bladder cancer patients is influenced by tumor biology, immune variability, and genetic factors, impacting prognosis negatively.
- Non-responders to BCG therapy often require alternative treatments, facing a poorer prognosis compared to responders.
Katie S. Murray, DO, discusses why some patients do not respond to BCG therapy, exploring factors such as tumor biology and immune system dysfunction, and how this impacts their prognosis, while also addressing the challenges and unmet needs in treating these patients, including the current BCG shortages and how it is reshaping treatment approaches.
- Why do some patients not respond to BCG therapy and how may it impact their prognosis?
- What challenges or unmet needs do you face when treating these patients?
- Discuss your thoughts and opinions on the current BCG shortages. How is this changing how you are managing your patients?
Related Videos
Related Content
